MedPath

Tagged News

MacroGenics Secures $70 Million in ZYNYZ Royalty Deal, Extends Cash Runway Through 2027

Oncology
  • MacroGenics received a $70 million upfront payment from Sagard Healthcare Partners through a royalty purchase agreement for ZYNYZ, a PD-1 inhibitor approved for anal canal carcinoma and Merkel cell carcinoma.
  • The deal extends MacroGenics' cash runway through the first half of 2027, providing financial stability as the company advances its pipeline of antibody-drug conjugates and bispecific therapeutics.
  • Under new CEO Eric Risser's leadership, MacroGenics is focusing on advancing key programs including lorigerlimab for prostate cancer, MGC026 and MGC028 ADCs for solid tumors, and preparing MGC030 for clinical trials.
  • The company reported $176.5 million in cash reserves as of June 30, 2025, with total revenue of $22.2 million in Q2 2025, primarily driven by increased contract manufacturing services.

Nordic Capital Invests in Minerva Imaging to Build Global Radiopharmaceutical Platform

Targeted TherapyPrecision MedicineOncology
  • Nordic Capital has announced a strategic investment in Minerva Imaging, a Denmark-based contract research organization specializing in targeted radioligand therapies for cancer treatment.
  • The partnership aims to accelerate Minerva's international expansion and strengthen its integrated platform serving pharmaceutical and biotechnology companies in radiopharmaceutical development.
  • Minerva reported revenue of more than DKK 225 million ($35 million) in 2024 and employs over 150 professionals, including PhD-level scientists at its Copenhagen headquarters.
  • The global radiopharmaceuticals market is positioned for significant growth driven by increasing cancer incidence and growing demand for precision medicines.

Tang Capital's Concentra Biosciences Acquires Elevation Oncology for $0.36 Per Share in Latest Biotech Liquidation

Oncology
  • Elevation Oncology has agreed to be acquired by Concentra Biosciences, controlled by hedge fund Tang Capital Partners, for $0.36 per share in cash with additional contingent value rights.
  • The acquisition represents the latest example of investment firms targeting struggling biotech "zombies" worth less than their cash reserves for liquidation rather than strategic repositioning.
  • Elevation's lead cancer drug disappointed in clinical testing, forcing the company to shelve its program, lay off most staff, and trade below $1 per share for nearly a year.
  • The deal follows Tang Capital's previous acquisitions of struggling biotechs including Allakos, Jounce Therapeutics, and Kronos Bio through its liquidation-focused investment strategy.

Concentra Biosciences to Acquire Elevation Oncology for $0.36 Per Share Plus Contingent Value Rights

Oncology
  • Concentra Biosciences has entered into a definitive merger agreement to acquire Elevation Oncology for $0.36 in cash per share plus contingent value rights.
  • The contingent value rights include 100% of closing net cash exceeding $26.4 million and 80% of net proceeds from EO-1022 disposition within specified timeframes.
  • Elevation Oncology's Board of Directors unanimously approved the acquisition, with the tender offer expected to commence by June 23, 2025 and transaction closure anticipated in July 2025.
  • Company officers, directors and affiliates holding approximately 5.1% of common stock have signed agreements to tender their shares and support the merger transaction.

Complement 1 Raises $16M to Scale AI-Powered Cancer Lifestyle Platform with 90% Patient Adherence

Oncology
  • Complement 1 secured $16 million in seed funding led by Owl Ventures and Blume Ventures to scale its clinically validated lifestyle modification platform for cancer patients.
  • Clinical trials demonstrate the platform achieves over 90% patient adherence while reducing treatment side effects by 37%, pain by 18%, and improving sleep by 27%.
  • The evidence-based platform combines daily one-on-one CoActive coaching with AI-driven personalization, potentially reducing healthcare costs by up to 30% for cancer patients.
  • Research shows lifestyle modifications can reduce cancer recurrence by 35% and mortality by 37%, addressing a critical gap in oncology care delivery.

Secura Bio Initiates Phase 3 TERZO Trial of COPIKTRA for Rare T-Cell Lymphoma

Rare DiseaseOncology
  • Secura Bio has dosed the first patient in its Phase 3 TERZO study evaluating COPIKTRA (duvelisib) for relapsed or refractory nodal T-follicular helper cell lymphoma, a rare cancer with no established treatment standards.
  • The randomized controlled trial will compare duvelisib against investigator's choice of gemcitabine or bendamustine in approximately 124 patients across the European Union and United Kingdom.
  • COPIKTRA is the first US-approved dual PI3K-delta and PI3K-gamma inhibitor, currently indicated for chronic lymphocytic leukemia after at least two prior therapies.
  • Interim data from this first Phase 3 study of a PI3K inhibitor in this rare lymphoma indication is anticipated in early 2027.

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

NCT06522737RecruitingPhase 3
SecuraBio
Posted 5/19/2025

Glenmark Pharmaceuticals Receives DCGI Approval to Launch BRUKINSA for Five B-Cell Malignancies in India

Drug ApprovalOncology
  • Glenmark Pharmaceuticals has received DCGI approval to launch zanubrutinib (BRUKINSA) in India, marking the first BTK inhibitor approved for treating five distinct B-cell malignancies.
  • BRUKINSA is approved for chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma.
  • The drug is already approved in more than 70 countries globally and is supported by clinical evidence from pivotal trials including ALPINE, ASPEN, and SEQUOIA.
  • The launch represents a significant expansion of innovative oncology treatments for Indian patients through Glenmark's partnership with BeiGene (now BeOne Medicines).

EMA Extends Shelf Life of Veterinary Cancer Drug MASIVET to 48 Months

Oncology
  • The European Medicines Agency has approved extending the shelf life of MASIVET, a veterinary cancer treatment, from 36 months to 48 months for the 50mg tablet formulation.
  • MASIVET is specifically indicated for treating non-resectable mast cell tumors in dogs with Grade 2 or 3 severity and confirmed c-kit tyrosine kinase receptor mutations.
  • The shelf-life extension provides greater inventory management flexibility for veterinarians and caregivers while reducing product expiration risks across all EU countries.
  • This regulatory approval ensures continued treatment availability and supports veterinarians in providing optimal care for canine cancer patients.

Health Canada Approves First-of-Its-Kind Antibody-Drug Conjugate for Multiple Myeloma Treatment

Drug ApprovalOncologyTargeted Therapy
  • Health Canada has approved Blenrep, a first-of-its-kind antibody-drug conjugate for multiple myeloma treatment, representing a significant advancement for patients with this incurable blood cancer.
  • The drug features a unique dual mechanism that combines targeted antibody binding with attached cytotoxic payload to specifically kill myeloma cells in the bone marrow.
  • Blenrep is administered to patients who have undergone stem cell transplant and one prior line of therapy, offering an "off-the-shelf" treatment option that requires no special preparation.
  • The approval adds another therapeutic option to the treatment chain for multiple myeloma patients, potentially extending disease control for years and offering hope for significantly longer survival.

Kelun-Biotech Raises $250 Million in Largest Hong Kong Biopharma Follow-On Offering in 12 Months

Oncology
  • Kelun-Biotech successfully completed a $250 million share placement on June 5, 2025, representing the largest follow-on offering in Hong Kong's biopharma sector over the past 12 months.
  • The offering was multiple times oversubscribed with strong participation from global institutional investors, leading to an upsize from the initially targeted $200 million.
  • Proceeds will fund R&D, clinical trials, manufacturing and commercialization of the company's innovative drug pipeline, which includes over 30 ongoing projects and a leading ADC platform.
  • The company focuses on solid tumors, autoimmune, inflammatory and metabolic diseases, with 3 approved products, 1 in NDA stage, and over 10 in clinical development.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.